1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3
Michael J Kelly III, Mark E Layton, Philip E Sanderson: Inhibitors of Akt activity. Merck & Co, Matthew A Leff, David A Muthard, August 18, 2009: US07576209 (5 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4
Mark E Layton, Michael J Kelly III: Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, February 10, 2015: US08952005 (2 worldwide citation)

The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glut ...


5
Michael J Kelly III, Mark E Layton, Philip E Sanderson: Substituted naphthyridine compounds as inhibitors of Akt activity. Merck Sharp & Dohme, Yong Zhao, David A Muthard, Matthew A Leff, October 16, 2012: US08288407

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


6
Hannah D Fiji, Michael J Kelly III, Jeffrey C Kern, Mark E Layton, Joseph E Pero, Alexander J Reif, Michael A Rossi: Imidazopyridin-2-one derivatives. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, April 19, 2016: US09315518

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


7
Mark E Layton, Joseph E Pero, Hannah Fiji, Michael J Kelly III, Pablo de Leon, Michael A Rossi, Kevin F Gilbert, Anthony J Roecker, Zhijian Zhao, Swati I P Mercer, Scott Wolkenberg, James Mulhearn, Lianyun Zhao, Dansu Li: Benzoxazolinone compounds with selective activity in voltage-gated sodium channels. Merck Sharp & Dohme, H Eric Fischer, John C Todaro, March 1, 2016: US09273040

Disclosed are compounds of Formula (A) or a salt thereof, wherein “Het”, Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A) or their ...


8
Joseph E Pero, Hannah D G F Lehman, Mark E Layton, Michael A Rossi, Michael J Kelly III: N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels. Merck Sharp & Dohme, John C Todaro, H Eric Fischer, July 12, 2016: US09388179

Disclosed are compounds of Formula AA and Formula AB: wherein “Heteroaryl-1”, RA1, RA2, RB1, and RC are defined herein, which novel compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the c ...


9
Joseph E Pero, Hannah D G F Lehman, Michael J Kelly III, Lianyun Zhao, Michael A Rossi, Dansu Li, Kevin F Gilbert, Scott Wolkenberg, James Mulhearn, Mark E Layton, Pablo de Leon: Benzoxazolinone compounds with selective activity in voltage-gated sodium channels. Merck Sharp & Dohme, H Eric Fischer, John C Todaro, April 18, 2017: US09624208

Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein “Het”, Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A ...


10
Michael J Kelly III, Mark E Layton, Philip E Sanderson: Inhibitors of akt activity. Merck & Co, June 30, 2011: US20110160183-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...



Click the thumbnails below to visualize the patent trend.